Found: 4
Select item for more details and to access through your institution.
Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 4, p. 1029, doi. 10.1007/s13555-023-00906-2
- By:
- Publication type:
- Article
Guselkumab dosing interval optimization in adult patients with moderate‐to‐severe psoriasis switching from ustekinumab.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 11, p. 1, doi. 10.1111/dth.15835
- By:
- Publication type:
- Article
Guselkumab as a switching strategy after anti‐TNFα, anti‐IL17, or anti‐IL12/23 therapies in moderate‐to‐severe psoriasis.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 10, p. 1, doi. 10.1111/dth.15760
- By:
- Publication type:
- Article
Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.
- Published in:
- Life (2075-1729), 2022, v. 12, n. 9, p. 1412, doi. 10.3390/life12091412
- By:
- Publication type:
- Article